First Trust Advisors LP Increases Position in CME Group Inc (CME)

First Trust Advisors LP lifted its position in CME Group Inc (NASDAQ:CME) by 11.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 308,620 shares of the financial services provider’s stock after purchasing an additional 30,572 shares during the period. First Trust Advisors LP owned 0.09% of CME Group worth $52,530,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Meeder Asset Management Inc. raised its stake in CME Group by 84.8% in the second quarter. Meeder Asset Management Inc. now owns 789 shares of the financial services provider’s stock worth $129,000 after buying an additional 362 shares in the last quarter. Kaizen Advisory LLC raised its stake in CME Group by 151.9% in the second quarter. Kaizen Advisory LLC now owns 816 shares of the financial services provider’s stock worth $134,000 after buying an additional 492 shares in the last quarter. Sun Life Financial INC raised its stake in CME Group by 267.7% in the second quarter. Sun Life Financial INC now owns 923 shares of the financial services provider’s stock worth $151,000 after buying an additional 672 shares in the last quarter. Lourd Capital LLC bought a new position in CME Group in the third quarter worth approximately $210,000. Finally, HMS Capital Management LLC bought a new position in CME Group in the second quarter worth approximately $207,000. Hedge funds and other institutional investors own 84.29% of the company’s stock.

A number of brokerages recently commented on CME. BidaskClub raised shares of CME Group from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 9th. Jefferies Financial Group boosted their price objective on shares of CME Group to $203.00 and gave the stock a “buy” rating in a research note on Monday, October 8th. Deutsche Bank reissued a “buy” rating and issued a $192.00 price objective (up previously from $185.00) on shares of CME Group in a research note on Thursday, October 11th. Wells Fargo & Co boosted their price objective on shares of CME Group from $175.00 to $177.00 and gave the stock a “market perform” rating in a research note on Friday. Finally, Rosenblatt Securities began coverage on shares of CME Group in a research note on Wednesday, September 5th. They issued a “neutral” rating and a $177.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $181.54.

Shares of CME stock opened at $179.39 on Tuesday. The firm has a market cap of $60.65 billion, a PE ratio of 28.95, a price-to-earnings-growth ratio of 3.37 and a beta of 0.64. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.08 and a current ratio of 1.09. CME Group Inc has a 12-month low of $135.61 and a 12-month high of $183.79.

CME Group (NASDAQ:CME) last issued its quarterly earnings results on Thursday, October 25th. The financial services provider reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.03. The business had revenue of $904.20 million for the quarter, compared to the consensus estimate of $910.50 million. CME Group had a return on equity of 9.18% and a net margin of 113.67%. On average, analysts predict that CME Group Inc will post 6.63 earnings per share for the current year.

In other news, President Bryan T. Durkin sold 11,509 shares of the company’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $162.01, for a total transaction of $1,864,573.09. Following the transaction, the president now directly owns 64,862 shares of the company’s stock, valued at $10,508,292.62. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ronald A. Pankau sold 260 shares of the company’s stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $163.17, for a total value of $42,424.20. Following the transaction, the director now directly owns 3,900 shares in the company, valued at $636,363. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,188 shares of company stock worth $4,973,607. Insiders own 0.43% of the company’s stock.

CME Group Profile

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.

Further Reading: Understanding Stock Ratings

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply